- Home
- NEPH vs INAB Comparison
NEPH vs INAB Comparison
Compare NEPH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- INAB
- Stock Information
- Founded
- NEPH 1997
- INAB 2016
- Country
- NEPH United States
- INAB United States
- Employees
- NEPH N/A
- INAB N/A
- Industry
- NEPH Medical/Dental Instruments
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- NEPH Health Care
- INAB Health Care
- Exchange
- NEPH Nasdaq
- INAB Nasdaq
- Market Cap
- NEPH 16.8M
- INAB 18.8M
- IPO Year
- NEPH 2004
- INAB 2021
- Fundamental
- Price
- NEPH $1.81
- INAB $0.15
- Analyst Decision
- NEPH Buy
- INAB Strong Buy
- Analyst Count
- NEPH 1
- INAB 2
- Target Price
- NEPH $5.00
- INAB $3.60
- AVG Volume (30 Days)
- NEPH 13.3K
- INAB 942.2K
- Earning Date
- NEPH 05-08-2025
- INAB 05-08-2025
- Dividend Yield
- NEPH N/A
- INAB N/A
- EPS Growth
- NEPH N/A
- INAB N/A
- EPS
- NEPH 0.01
- INAB N/A
- Revenue
- NEPH $14,162,000.00
- INAB N/A
- Revenue This Year
- NEPH $9.23
- INAB N/A
- Revenue Next Year
- NEPH $12.99
- INAB N/A
- P/E Ratio
- NEPH $277.38
- INAB N/A
- Revenue Growth
- NEPH N/A
- INAB N/A
- 52 Week Low
- NEPH $1.36
- INAB $0.14
- 52 Week High
- NEPH $2.55
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- NEPH 55.06
- INAB 27.86
- Support Level
- NEPH $1.66
- INAB $0.14
- Resistance Level
- NEPH $2.22
- INAB $0.25
- Average True Range (ATR)
- NEPH 0.13
- INAB 0.02
- MACD
- NEPH 0.03
- INAB -0.00
- Stochastic Oscillator
- NEPH 43.84
- INAB 16.99
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.